Novartis Meningitis Vaccine Performing Well In Late-stage Trials

September 13, 2010 · Filed Under Meningitis · Comment 

According to Bloomberg, Novartis AG (NVS) recently reported that phase III trials of their Meningitis B vaccine were meeting its goals. While many forms of the disease are preventable, this vaccine is aimed at treating infants, who are particularly susceptible, and to whom the disease is most lethal. Shares of NVS are up .41% on moderate volume.

-Michael B. Sauter

    Subscribe to BioHealth Investor BioHealth Investor RSS Feed